Navigation Links
The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients
Date:9/18/2007

WHITE PLAINS, N.Y., Sept. 18 /PRNewswire/ -- Millennium Pharmaceuticals and Johnson & Johnson have reported that an interim analysis of a large, randomized, international Phase III trial comparing melphalan-prednisone (MP) with MP in combination with Velcade(R) (bortezomib) showed that the patients treated on the Velcade arm did better. These patients, who are not eligible for a stem cell transplant, experienced statistically significant benefit in terms of time-to-disease progression, complete response rate, progression-free survival and overall survival. Patients treated on the MP arm of the trial have the opportunity to switch over to the Velcade arm.

Detailed results from this trial will be presented at the American Society of Hematology annual meeting in early December.

"This is extremely encouraging news for myeloma patients," said Bart Kamen, M.D., Ph.D., the Society's chief medical officer. "However, while these results are very exciting, the Society reminds patients not to make any changes in their treatment regimen without speaking to their doctor first."

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the Society's Information Resource Center (IRC), a call center st
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
2. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
3. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
4. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
5. Major Gene Study Uncovers Secrets of Leukemia
6. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkins Lymphoma Appears Safe and Active in a Phase I/II Study
9. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
10. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
11. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... Sept. 9 Roche NimbleGen (SIX: RO, ROG; Pink ... Viejo) based genomic services provider Ambry Genetics has officially ... NimbleGen SeqCap EZ Exome workflow. They will provide ... with next-generation sequencing services for genetic research. Ambry Genetics ...
... Texas, Sept. 9 Luminex Corporation (Nasdaq: ... UBS Global Life Sciences Conference to be held September ... York. (Logo:   http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... by Patrick J. Balthrop, president and chief executive officer, ...
Cached Medicine Technology:Ambry Genetics Becomes First Certified Service Provider in US for NimbleGen SeqCap EZ Exome 2Ambry Genetics Becomes First Certified Service Provider in US for NimbleGen SeqCap EZ Exome 3Luminex Corporation to Present at UBS Global Life Sciences Conference 2
(Date:4/18/2014)... 21, 2014) -- A group of scientists from ... the Sanders-Brown Center on Aging has found interesting ... neuropsychological function in Parkinson,s disease (PD). , ... the study, which assessed cognitive function in depressed ... dopamine replacement therapy commonly used to treat motor ...
(Date:4/18/2014)... The Gerontologist reports that among older ... decrease in anxiety about death and increases in life ... In particular, listening to gospel music is associated with ... in sense of control. , These associations are similar ... of both low- and high-socioeconomic status. , The article, ...
(Date:4/18/2014)... Hopkins University School of Medicine researchers have been awarded ... diabetes, Novo Nordisk announced this month. Of the 110 ... Obesity Biologics Science Forum Program, only four projects were ... researchers. They are Jonathan Powell, M.D., Ph.D.; G. William ... Jonathan Powell, a professor of oncology, will use his ...
(Date:4/18/2014)... 2014) Benaroya Research Institute at Virginia Mason (BRI) ... particular molecule in metastatic breast cancer reduces both the ... metastases. BRI scientists have found in models of the ... 60 - 80 percent and can keep the tumor ... million five-year grant comes from the National Cancer Institute ...
(Date:4/18/2014)... Diego, Calif. (April 18, 2014) ― A new study ... analyzing weekly patterns in health-related Google searches reveals a ... health strategies. , Investigators from San Diego ... and the Monday Campaigns, analyzed "healthy" Google searches (searches ... e.g., "healthy diet") originating in the U.S. from 2005 ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2
... Oct. 27 Inspired by recent breakthroughs in research, today ... initiative entitled Research to Reality: Funding Progress. ... progress of crucial research, and bring promise to reality. ... battle with Rett syndrome in 2003 at age 16, will ...
... 2009 A diverse group of health care ... week that are designed to promote better medication ... The group, which includes the American College of ... Stores, the National Consumers League and the Pharmaceutical ...
... the world use medicines based on statins to lower their ... published in the prestigious journal PNAS, shows that statins may ... Statins lower cholesterol by blocking certain enzymes involved in our ... important lipids in the body, such as the lipids that ...
... developing a range of miniaturised wearable and track-side sensors, ... British athletes improve their performance on the world stage, ... will be officially launched tomorrow (28 October 2009). ... Sensing (ESPRIT) project is funded by the EPSRC and ...
... lead and some had known skin allergens , TUESDAY, Oct. ... are set to paint their faces this Halloween to look ... according to a new report released just in time for ... Safe Cosmetics, is titled: Pretty Scary: Could Halloween Face ...
... 27 Polar ( www.polarusa.com ), the leader in ... technology today introduced two new training computers designed to ... clear guidance, feedback and easy-to-use features including heart rate, which can ... person is using a heart rate monitor for the first time ...
Cached Medicine News:Health News:IRSF Receives 1 Million Dollar Matching Gift 2Health News:IRSF Receives 1 Million Dollar Matching Gift 3Health News:IRSF Receives 1 Million Dollar Matching Gift 4Health News:Experts offer policy recommendations for improving medication adherence 2Health News:Experts offer policy recommendations for improving medication adherence 3Health News:Major research collaboration will improve British athletes' performance on world stage 2Health News:Major research collaboration will improve British athletes' performance on world stage 3Health News:Toxins Make Halloween Face Paints Scary 2Health News:Toxins Make Halloween Face Paints Scary 3Health News:Two New Easy-To-Use Training Computers from Polar Simplify the Benefits of Exercising with Heart Rate 2Health News:Two New Easy-To-Use Training Computers from Polar Simplify the Benefits of Exercising with Heart Rate 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: